CT-XEROX
A new global business survey commissioned by Xerox Holdings Corporation (NYSE:XRX) shows an estimated 82% of the workforce in respondents’ organizations will have returned to the workplace in 12-18 months’ time, on average. In preparation for a return, companies are investing in new resources to support a hybrid remote / in-office workforce, with 56% increasing technology budgets and 34% planning to speed their digital transformation as a result of COVID-19.
The Xerox Future of Work Survey, conducted by the independent research firm Vanson Bourne, polled 600 IT decision makers including senior C-level professionals from the U.S., Canada, the U.K., Germany and France, whose organizations have at least 500 employees. Respondents reported challenges caused by the sudden transition to remote work, with 72% citing they were not fully prepared from a technology perspective. In addition to technology (29%), the biggest pain points during the required work from home period were communication breakdown across teams/employees (26%) and maintaining focus (25%).
“While there is no doubt the COVID-19 pandemic has changed the way we work, our research found that over time many companies plan to have most employees back in an office environment. This could be for a variety of reasons, including communication, speed of decision-making and talent development,” said Steve Bandrowczak, Xerox president and chief operations officer. “At the same time, the sudden shutdown and ongoing hybrid work environment has exposed technology gaps that require new or additional investment in the coming months.”
Key survey findings and Xerox takeaways include:
-
Businesses plan to return most employees to the office, though expanded remote work policies are here to stay.
Prior to work from home requirements being imposed, 33% of respondents said network/data security and privacy was their biggest concern with a remote workforce; 24% cited employee productivity followed by 16% citing technology infrastructure. These concerns, coupled with the belief held by 95% of respondents that in-person communication is important for personal development and assessing talent, indicate widespread remote work will not replace more traditional workspaces.
However, now that businesses are more comfortable with remote work, attitudes and policies of C-suite leaders and IT decision makers are shifting. Among the countries polled, the U.S. is the most likely to have an increase in confidence in remote working (86%), followed by the U.K. (80%), Germany (80%), Canada (77%), and France (75%). Furthermore, 58% plan to change their work from home policy within the next year, highlighting the need for companies to support a hybrid workforce.
Our takeaway: Employees may not be going back to the office all at once — or even in the same capacity as before — but the need for organizations to support a hybrid workforce is here for the foreseeable future.
-
Sudden stay-at-home orders quickly revealed technology gaps.
The rapid transition to remote work was difficult for most businesses, with only 28% saying they were fully prepared and 29% citing technology as their biggest pain point. Among the specific countries polled, France was the least likely to be fully prepared for the sudden transition to remote work, while the U.S. was the most likely to be fully prepared. With regards to technology specifically, respondents said their top challenges were remote IT support (35%), inadequate workflow solutions (27%), lack of communications and collaboration tools (22%) and lack of cloud-based solutions (10%). 85% of business leaders also missed the accessibility and ease of use of their office printers, with U.S. respondents missing them the most (93%) followed by Germany (92%) and France (91%).
Our takeaway : To mitigate against future disruptions, such as the rapid transition to remote work resulting from COVID-19, companies will look to invest in new technologies and seek added capability from existing tools to accelerate their processes digital transformation.
-
Technology purchasing priorities are shifting to better support employees.
As a result of technology gaps uncovered by having a mostly remote workforce, 70% of IT decision makers globally are reevaluating their budget spend, with companies increasing investment in remote technology resources (55%) or a hybrid of remote and in-office resources (40%). The pandemic also has businesses prioritizing investments in cloud-based software (65%), remote IT (63%) support and collaboration software (52%).
Hardware such as laptops and printers were another important consideration, especially for companies based in France, with 22% of respondents citing it as the most important need when it comes to technology, productivity and their overall work experience.
Our Takeaway : COVID-19 is feeding digital transformation plans and companies are placing a renewed focus on meeting employees’ needs with both hardware and software.
For more information, visit www.Xerox.com/MakeNowWork .
Methodology
The survey of 600 respondents located in the U.S., Canada, U.K., Germany and France was conducted by independent research firm Vanson Bourne in May 2020. Respondents included IT decision makers (including senior C-level professionals), all from organizations with at least 500 employees across a range of sectors, including business and professional services, retail, health care, financial services, and travel and hospitality.
About Xerox
Xerox Holdings Corporation makes every day work better. We are a workplace technology company building and integrating software and hardware for enterprises large and small. As customers seek to manage information across digital and physical platforms, Xerox delivers a seamless, secure and sustainable experience. Whether inventing the copier, Ethernet, the laser printer or more, Xerox has long defined the modern work experience. Learn how that innovation continues at xerox.com .
Note: To receive RSS news feeds, visit https://www.news.xerox.com . For open commentary, industry perspectives and views, visit http://twitter.com/xerox , http://www.facebook.com/XeroxCorp , https://www.instagram.com/xerox/ , http://www.linkedin.com/company/xerox , http://www.youtube.com/XeroxCorp .
Xerox® is a trademark of Xerox Corporation in the United States and/or other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200615005365/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
